Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecific antibody

Blood

Volumn 89, Issue 6, 1997, Pages 2042-2047

  Hartmann, Frank ^b   Renner, Christoph ^b   Jung, Wolfram ^b   Deisting, Christina ^b   Juwana, Marietta ^b   Eichentopf, Bertram ^b   Kloft, Michael ^b   Pfreundschuh, Michael ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC ANTIBODY; CD16 ANTIGEN; CD30 ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HRS 3 A 9; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; FEMALE; FEVER; HODGKIN DISEASE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LYMPHADENITIS; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH;

EID: 0030974954     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v89.6.2042     Document Type: Article

References (29)

1. DeVita VT: The consequences of chemotherapy of Hodgkin's disease: The 10th David A. Karnofsky Memorial Lecture. Cancer 47:1, 1987
2. Milstein C, Cuello AC: Hybrid hybridomas and their use in immunohistochemistry. Nature 305:537, 1983
3. Renner C, Pfreundschuh M: Tumor therapy by immune recruitment with bispecific antibodies. Immunol Rev 145:179, 1995
4. Hombach A, Jung W, Pohl C, Renner C, Sahin U, Schmits R, WoIf J, Kapp U, Diehl V, Pfreundschuh M: A CD16/CD30 bispecific antibody induces lysis of Hodgkin cells by unstimulated natural killer cells in vitro and in vivo. Int J Cancer 55:830, 1993
5. Renner C, Jung W, Sahin U, Denfeld R, Pohl C, Trümper L, Hartmann F, Diehl V, van Lier R, Pfreundschuh M: Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells. Science 264:833, 1994
6. Renner C, Bauer S, Sahin U, Jung W, van Lier R, Jacobs G, Held G, Pfreundschuh M: Cure of disseminated xenografted human Hodgkin's tumors by bispecific monoclonal antibodies and human T cells: The role of human T-cell subsets in a preclinical model. Blood 87:2930, 1996
7. Stein H, Mason DY, Gerdes J, O'Connor N, Wainscoat J, Palleses G, Falini B, Delsoi G, Lemke H Schwarting R, Lennert K: The expression of Hodgkin's disease antigen Ki-1 in reactive and neoplastic lymphoid tissue: Evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 66:848, 1985
8. Investigator's Handbook. A Manual for Participants in Clinical Trials of Investigational Agents. Cancer Therapy Evaluation Program. Bethesda, MD, Division of Cancer Treatment, National Cancer Institute, 1993
9. Pohl C, Renner C, Schwonzen M, Sieber M, Lorenz P, Pfreundsch uh M, Diehl V: Anti-idiotype vaccine against Hodgkin's lymphoma: Induction of B-and T-cell immunity across species barriers against CD30 antigen by murine monoclonal internal image antibodies. Int J Cancer 50:958, 1992
10. Fanger MW, Morganelli PM, Guyre PM: Bispecific antibodies. Crit Rev Immunol 12:101, 1992
11. Elsässer D, Valerius T, Repp R, Weiner G, Do Y, Kalden JR, van de Winkel JGJ, Stevenson GT, Glennie MJ, Gramatzki M: HLA class II as a potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with granulocyte colony-stimulating factor. Blood 87:3808, 1996
12. 1 lymphoma: Increased efficacy with multiple injections and CD28-induced costimulation. Blood 87:4390, 1996
13. Ely P, Wallace PK, Givan AL, Graziano RF, Guyre PM, Fanger MW: Bispecific-armed, interferon γ-primed macrophage-mediated phagocytosis of malignant non-Hodgkin's lymphoma. Blood 87:3813, 1996
14. Nitta T, Sato K, Yagita H, Okumura F, Ishii S: Preliminary trial of specific targeting therapy against malignant glioma. Lancet 335:368, 1990
15. Bolhuis RL, Lamers CH, Goey SH, Eggermont AM, Trimbos JB, Stoter G, Lanzavecchia A, di Re E, Miotti S, Raspagliesi F, Rivoltini L, Colnaghi MI: Adoptive immunotherapy of ovarian carcinoma with bs-MAb-targeted lymphocytes: A multicenter study. Int J Cancer Suppl 7:78, 1992
16. Kroesen BJ, ter Haar A, Spakman H, Willemse P, Sleijfer DT, de Vries EG, Mulder NH, Berendsen HH, Limburg PC, The TH, de Leij L: Local antitumour treatment in carcinoma patients with bispecific monoclonal antibody redirected T cells. Cancer Immunol Immunother 37:400, 1993
17. Kroesen BJ, Buter J, Sleijfer DT, Janssen RA, van der Graaf WT, The TH, de Leij L, Mulder NH: Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2. Br J Cancer 70:652, 1994
18. De Gast GC, Haagen IA, van Houten AA, Klein SC, Duits AJ, de Weger RA, Vroom TM, Clark MR, Phillips S, van Dijk AJ, Bast BJEG: CD8 T cell activation after intravenous administration of CD3 × CD19 bispecific antibody in patients with non-Hodgkin lymphoma. Cancer Immunol Immunother 40:390, 1995
19. Canevari S, Stoter G, Arienti F, Bolis G, Colnaghi MI, di Re EM, Eggermont AM, Goey SH, Gratama JW, Lamers CH: Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody. J Natl Cancer Inst 87:1463, 1995
20. Valone FH, Kaufman PA, Guyre PM, Lewis LD, Memoli V, Deo Y, Graziano R, Fisher JL, Meyer L, Mrozek-Orlowski M, Wardwell K, Guyre V, Morley TL, Arvizu C, Fanger MW: Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene Her-2/neu. J Clin Oncol 13:2281, 1995
21. Weiner LM, Clark JI, Davey M, Li WS, de Palazzo IG, Ring DB, Alpaugh RK: Phase I Trial of 2B1, a bispecific monoclonal antibody targeting c-erB-2 and FcγRIII. Cancer Res 55:4586, 1995
22. Slivnick DJ, Ellis TM, Nawrocki N, Fisher RI: The impact of Hodgkin's disease on the immune system. Semin Oncol 17:673, 1990
23. Dillman RO: Antibodies as cytotoxic therapy. J Clin Oncol 12:1497, 1994
24. Reilly RM, Kirsh J, Gallinger S, Thiessen JJ, Damani M, Hay K, Polihronis J, Schmocker B, Odze R, Houle S: Compartmental analysis of the pharmacokinetics of radio iodinated monoclonal antibody B72.3 in colon cancer patients. Nucl Med Biol 20:57, 1993
25. Lamers CHJ, Gratama JW, Warnaar SO, Stoter G, Bolhuis RLH: Inhibition of bispecific monoclonal antibody (bsAb)-targeted cytolysis by human anti-mouse antibodies in ovarian carcinoma patients treated with bsAb-targeted activated T-lymphocytes. Int J Cancer 60:450, 1995
26. Mack M, Riethmüller G, Kufer P: A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc Natl Acad Sci USA 92:7021, 1995
27. Holliger P, Prospero T, Winter G: Diabodies: Small bivalent and bispecific antibody fragments. Proc Natl Acad Sci USA 90:6444, 1993
28. Caligiuri MA, Murray C, Robertson MJ, Wang E, Cochran K, Cameron C, Schow P, Ross ME, Klumpp TR, Soiffer RJ, Smith KA, Ritz JA: Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2. J Clin Invest 91:123, 1993
29. Sahin U, Kraft-Bauer S, Ohnesorge S, Pfreundschuh M, Renner C: Interleukin-12 increases bispecific-antibody-mediated natural killer cell cytotoxicity against human tumors. Cancer Immunol Immunother 42:9, 1996